Cross-cohort generalizability of machine learning models for early-stage node-negative breast cancer relapse prediction
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Adjuvant therapy decision in early-stage node-negative breast cancer remains one of the most challenging problems in oncology. Although most patients in this population achieve favorable outcomes with endocrine therapy alone, a subset remains at risk of relapse and may benefit from chemotherapy. Accurate identification of high-risk and low-risk patients is therefore essential to prevent both undertreatment and overtreatment.
Methods
In this study, machine learning models were assessed using MSK-IMPACT (n=645) and METABRIC (n=503) cohorts comprising node-negative stage I-II breast cancer patients. Three experimental settings were evaluated: training on MSK-IMPACT and testing on METABRIC, the reverse direction, and five-fold cross-validation on the combined cohort. Sensitivity analysis and data harmonization were applied to identify and mitigate cohort-specific bias. Survival analysis, SHapley Additive exPlanations (SHAP) interpretability, and ablation analyses were performed to validate clinical relevance and characterize feature contributions.
Results
The combined cohort model achieved an area under the receiver operating characteristic curve (AUC) of 0.788 ± 0.028 across five-fold cross-validation, while bidirectional cross-cohort validation yielded AUC of 0.741 when testing on MSK-IMPACT and AUC of 0.714 when testing on METABRIC. Survival validation on METABRIC out-of-fold predictions from the combined cohort model showed hazard ratios of 3.01 (95% CI: 2.28–3.98) for disease-free survival and 2.35 (95% CI: 1.79–3.09) for overall survival, consistent across Luminal A, Luminal B, and Triple-Negative subtypes.
Conclusion
Validated across two geographically independent cohorts, the proposed model enables cost-effective, gene expression–free identification of patients at high-risk of distant relapse and may facilitate adjuvant chemotherapy decision-making in early-stage node-negative breast cancer.
